(VTRS) Viatris - Ratings and Ratios
Brand, Generic, Biosimilar, Complex, Dose
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 30.8% |
| Value at Risk 5%th | 47.2% |
| Relative Tail Risk | -6.85% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.32 |
| Alpha | -21.83 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.521 |
| Beta | 0.784 |
| Beta Downside | 1.056 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.02% |
| Mean DD | 16.37% |
| Median DD | 16.63% |
Description: VTRS Viatris October 31, 2025
Viatris Inc. (NASDAQ: VTRS) is a globally diversified healthcare company operating across North America, Europe, Greater China, Japan-Australia-New Zealand (JANZ), and emerging markets. Its business is organized into four geographic segments-Developed Markets, Greater China, JANZ, and Emerging Markets-and it markets a broad portfolio that includes prescription brands, generics, complex generics, and biosimilars covering therapeutic areas such as cardiovascular, CNS, diabetes, oncology, and respiratory diseases. Distribution channels span wholesale, retail, institutional, mail-order, e-commerce, and specialty pharmacies, and the firm also offers ancillary services like diagnostic clinics, educational programs, and digital health tools.
As of FY 2023, Viatris reported revenue of roughly $13.5 billion, with an adjusted EBITDA margin near 12%, reflecting the higher-margin mix from biosimilars and complex generics. The company’s growth is driven by three macro-level factors: (1) an aging global population increasing demand for chronic-disease therapies; (2) accelerating adoption of cost-effective biosimilars as payers tighten reimbursement policies; and (3) a projected 6% CAGR for the worldwide generic drug market through 2029, which benefits Viatris’s scale and diversified geographic footprint. Recent collaborations-such as the long-acting glatiramer acetate depot with Mapi Pharma and a Botox biosimilar with Revance-aim to expand its pipeline and capture additional market share in high-growth therapeutic niches.
If you want a data-rich, model-ready view of Viatris’s valuation dynamics, consider exploring the analytics on ValueRay for a deeper dive.
VTRS Stock Overview
| Market Cap in USD | 12,566m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2020-11-16 |
| Return 12m vs S&P 500 | -24.0% |
| Analyst Rating | 3.44 of 5 |
VTRS Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 5.60% |
| Yield on Cost 5y | 4.24% |
| Yield CAGR 5y | 13.30% |
| Payout Consistency | 57.4% |
| Payout Ratio | 20.6% |
VTRS Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 3.18% |
| CAGR/Max DD Calmar Ratio | 0.07 |
| CAGR/Mean DD Pain Ratio | 0.19 |
| Current Volume | 6472.4k |
| Average Volume | 7561k |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-3.69b TTM) > 0 and > 6% of Revenue (6% = 847.5m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -0.06pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 13.66% (prev 25.22%; Δ -11.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 1.98b > Net Income -3.69b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.16b) change vs 12m ago -2.98% (target <= -2.0% for YES) |
| Gross Margin 36.07% (prev 39.90%; Δ -3.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 34.17% (prev 33.62%; Δ 0.54pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -7.16 (EBITDA TTM -598.9m / Interest Expense TTM 471.9m) >= 6 (WARN >= 3) |
Altman Z'' -0.35
| (A) 0.05 = (Total Current Assets 9.29b - Total Current Liabilities 7.36b) / Total Assets 37.92b |
| (B) -0.00 = Retained Earnings (Balance) -48.2m / Total Assets 37.92b |
| (C) -0.08 = EBIT TTM -3.38b / Avg Total Assets 41.34b |
| (D) -0.12 = Book Value of Equity -2.75b / Total Liabilities 22.70b |
| Total Rating: -0.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 31.64
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield 6.11% = 3.05 |
| 3. FCF Margin 11.32% = 2.83 |
| 4. Debt/Equity 0.97 = 2.05 |
| 5. Debt/Ebitda -22.91 = -2.50 |
| 6. ROIC - WACC (= -15.57)% = -12.50 |
| 7. RoE -22.69% = -2.50 |
| 8. Rev. Trend -60.72% = -4.55 |
| 9. EPS Trend -54.78% = -2.74 |
What is the price of VTRS shares?
Over the past week, the price has changed by -4.29%, over one month by +3.88%, over three months by +1.90% and over the past year by -13.64%.
Is VTRS a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 5
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the VTRS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 12.1 | 13.3% |
| Analysts Target Price | 12.1 | 13.3% |
| ValueRay Target Price | 11.2 | 4.7% |
VTRS Fundamental Data Overview November 16, 2025
P/E Forward = 4.4563
P/S = 0.8897
P/B = 0.8265
P/EG = 0.1436
Beta = 0.837
Revenue TTM = 14.12b USD
EBIT TTM = -3.38b USD
EBITDA TTM = -598.9m USD
Long Term Debt = 12.49b USD (from longTermDebt, last quarter)
Short Term Debt = 2.06b USD (from shortTermDebt, last quarter)
Debt = 14.72b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.72b USD (from netDebt column, last quarter)
Enterprise Value = 26.18b USD (12.57b + Debt 14.72b - CCE 1.11b)
Interest Coverage Ratio = -7.16 (Ebit TTM -3.38b / Interest Expense TTM 471.9m)
FCF Yield = 6.11% (FCF TTM 1.60b / Enterprise Value 26.18b)
FCF Margin = 11.32% (FCF TTM 1.60b / Revenue TTM 14.12b)
Net Margin = -26.13% (Net Income TTM -3.69b / Revenue TTM 14.12b)
Gross Margin = 36.07% ((Revenue TTM 14.12b - Cost of Revenue TTM 9.03b) / Revenue TTM)
Gross Margin QoQ = 36.83% (prev 37.21%)
Tobins Q-Ratio = 0.69 (Enterprise Value 26.18b / Total Assets 37.92b)
Interest Expense / Debt = 0.81% (Interest Expense 119.6m / Debt 14.72b)
Taxrate = -1523 % (out of range, set to none) (120.3m / -7.90m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.26 (Total Current Assets 9.29b / Total Current Liabilities 7.36b)
Debt / Equity = 0.97 (Debt 14.72b / totalStockholderEquity, last quarter 15.22b)
Debt / EBITDA = -22.91 (negative EBITDA) (Net Debt 13.72b / EBITDA -598.9m)
Debt / FCF = 8.58 (Net Debt 13.72b / FCF TTM 1.60b)
Total Stockholder Equity = 16.27b (last 4 quarters mean from totalStockholderEquity)
RoA = -9.73% (Net Income -3.69b / Total Assets 37.92b)
RoE = -22.69% (Net Income TTM -3.69b / Total Stockholder Equity 16.27b)
RoCE = -11.74% (EBIT -3.38b / Capital Employed (Equity 16.27b + L.T.Debt 12.49b))
RoIC = -11.47% (negative operating profit) (EBIT -3.38b / (Assets 37.92b - Curr.Liab 7.36b - Cash 1.11b))
WACC = 4.10% (E(12.57b)/V(27.29b) * Re(8.91%) + (debt cost/tax rate unavailable))
Discount Rate = 8.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.99%
[DCF Debug] Terminal Value 73.36% ; FCFE base≈1.72b ; Y1≈1.55b ; Y5≈1.33b
Fair Price DCF = 17.93 (DCF Value 20.65b / Shares Outstanding 1.15b; 5y FCF grow -12.44% → 3.0% )
EPS Correlation: -54.78 | EPS CAGR: 0.0% | SUE: 1.23 | # QB: 2
Revenue Correlation: -60.72 | Revenue CAGR: -1.10% | SUE: 2.32 | # QB: 2
Additional Sources for VTRS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle